| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/11/2002 | WO2002053558A1 Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists |
| 07/11/2002 | WO2002053557A1 Novel sulfamides and their use as endothelin receptor antagonists |
| 07/11/2002 | WO2002053547A1 Alkanoic acid derivatives, process for their production and use thereof |
| 07/11/2002 | WO2002053543A1 Pyridone derivative having affinity for cannabinoid 2-type receptor |
| 07/11/2002 | WO2002053533A2 Kappa opioid receptor ligands |
| 07/11/2002 | WO2002053525A1 Perfluoronated cycle-containing tertiary amines used as a basis for gas-conveying emulsions and device for the production thereof |
| 07/11/2002 | WO2002053523A1 Tropolone derivative |
| 07/11/2002 | WO2002053522A2 Novel estrogen receptor ligands and methods i |
| 07/11/2002 | WO2002053519A2 Hydrophobic polyamine analogs and methods for their use |
| 07/11/2002 | WO2002053191A1 Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof |
| 07/11/2002 | WO2002053190A2 Particles for inhalation having sustained release properties |
| 07/11/2002 | WO2002053171A2 Use of intermediate-conductance potassium channels and modulators for the diagnosis and treatment of illnesses having disturbed keratinocyte activity |
| 07/11/2002 | WO2002053167A2 Pharmaceutical combination for the treatment of tissue damage owing to an arterial irrigation defect |
| 07/11/2002 | WO2002053150A1 Preventives for wound adhesion |
| 07/11/2002 | WO2002053144A1 Regulation of organic nitrate tolerance |
| 07/11/2002 | WO2002053142A2 Compositions and methods for enhancing cytokine activity and treating hypotension associated with the administration of cytokines |
| 07/11/2002 | WO2002053137A2 Pharmaceutical composition for treatment of phimosis using topical corticosteroid |
| 07/11/2002 | WO2002053130A2 Sustained release drug delivery devices with coated drug cores |
| 07/11/2002 | WO2002053100A2 Pharmaceutical dosage form for oral administration of low molecular weight heparin |
| 07/11/2002 | WO2002053099A2 Methods and compositions for treating periodontal disease |
| 07/11/2002 | WO2002053097A2 Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination |
| 07/11/2002 | WO2002053091A2 Medicinal combination of a biguanine (metformin) and arginine |
| 07/11/2002 | WO2002053089A2 Stable skin conditioning compositions containing retinoid boosters |
| 07/11/2002 | WO2002052955A1 Nutritional and therapeutical preparations having antioxidant activity |
| 07/11/2002 | WO2002041918A3 Use of a triple combination comprising a 5ht3 antagonist, a 5ht4 agonist and a laxative for promoting intestinal lavage |
| 07/11/2002 | WO2002036734A3 Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors |
| 07/11/2002 | WO2002036605A3 Estrone-derivatives having cytoprotective activity |
| 07/11/2002 | WO2002028480A3 Methods of therapy for b-cell malignancies |
| 07/11/2002 | WO2002028349A3 Method of treating cancer using dithiocarbamate derivatives |
| 07/11/2002 | WO2002024632A3 Substituted aminopropoxyaryl derivatives useful as agonists for lxr |
| 07/11/2002 | WO2002020724A3 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 07/11/2002 | WO2002018348A3 Quinazoline derivatives as alpha-1 adrenergic antagonists |
| 07/11/2002 | WO2002017914A8 Fused pyrrolocarbazoles against inflammation |
| 07/11/2002 | WO2002014511A3 Regulation of human p2y1-like g protein-coupled receptor |
| 07/11/2002 | WO2002010199A3 C3b/c4b complement receptor-like molecules and uses thereof |
| 07/11/2002 | WO2002008221A3 Capsaicin receptor ligands |
| 07/11/2002 | WO2001096311A3 Hmg-coa reductase inhibitors and their use as medicaments for the treatment of cholesterol related diseases |
| 07/11/2002 | WO2001091783A3 Methods and compositions for producing a neurosalutary effect in a subject |
| 07/11/2002 | WO2001082918A8 Method for the prevention of apoptosis |
| 07/11/2002 | WO2001081412A3 Isolated human transporter proteins, nucleic acid molecules encoding the same, and uses thereof |
| 07/11/2002 | WO2001079445A3 Pluripotent cells comprising allogenic nucleus and mitochondria |
| 07/11/2002 | WO2001076556A3 Lipid-based drug delivery systems against parasitic infections |
| 07/11/2002 | WO2001074389A3 Improved treatment of neovascularization |
| 07/11/2002 | WO2001068067A3 Use of deramciclane for the treatment of anxiety and depression |
| 07/11/2002 | WO2001056551A3 Method and formulation for treatment of vasoconstriction |
| 07/11/2002 | WO2001046443A3 Proteases |
| 07/11/2002 | WO2001044512A3 Method of identifying ligands for the peroxisome proliferator activated receptor gamma using differential gene expression |
| 07/11/2002 | WO2001044473A3 Polypeptides and nucleic acids encoding same |
| 07/11/2002 | WO2001039763A3 Use of methylol-containing compounds for the manufacture of a medicament for the treatment of tumors |
| 07/11/2002 | WO2001034205A3 Use of lytic toxins and toxin conjugates |
| 07/11/2002 | WO2001024785A3 Dihydroorotate dehydrogenase inhibitors for the treatment of viral-mediated diseases |
| 07/11/2002 | WO2001017568A3 Bioconjugation in vivo to pulmonary or blood components |
| 07/11/2002 | WO2001016120A9 Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
| 07/11/2002 | WO2000075144A9 Peroxynitrite decomposition catalysts and methods of use thereof |
| 07/11/2002 | WO2000073263A9 Cytofectin dimers and methods of use thereof |
| 07/11/2002 | WO2000064911A9 Ligands for metabotropic glutamate receptors |
| 07/11/2002 | WO2000058472A9 Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
| 07/11/2002 | WO2000049937A9 Trpm-2 antisense therapy |
| 07/11/2002 | US20020091272 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 07/11/2002 | US20020091270 Sulfonamides containing oxazole and substituted thiophene rings, useful for treating hypertension, cardiovascular disease, asthma, pulmonary hypertension, inflammatory diseases, vision defects, menstrual disorders, renal failure |
| 07/11/2002 | US20020091266 Piperidine and pyrrolidine derivatives comprising a nitric oxide donor for treating stress |
| 07/11/2002 | US20020091265 4-phenyl-pyridine derivatives |
| 07/11/2002 | US20020091263 Biaryl substituted purine derivatives as potent antiproliferative agents |
| 07/11/2002 | US20020091262 Armoatic or heteroarmoatic compound containing substituted amides or thioamides |
| 07/11/2002 | US20020091261 Phthalazines with angiogenesis inhibiting activity |
| 07/11/2002 | US20020091259 Compounds useful as reversible inhibitors of cathepsin S |
| 07/11/2002 | US20020091157 Cyclic GMP (cGMP)-specific phosphodiesterase (PDE) inhibitor (e.g., exisulind) to reduce the side effects or increase the efficacy of treatment with an antineoplastic platinum coordination complex like cisplatin or carboplatin. |
| 07/11/2002 | US20020091153 Novel anandamide amidase inhibitors as analgesic agents |
| 07/11/2002 | US20020091151 Novel macrocycles and uses thereof |
| 07/11/2002 | US20020091143 Use of 4-substituted tetrahydropyridines for the manufacture of medicament s acting upon TGF-beta 1 |
| 07/11/2002 | US20020091138 Treating vascular proliferative disorders |
| 07/11/2002 | US20020091136 Pharmaceutical compositions containing cinchonine dichlorhydrate |
| 07/11/2002 | US20020091130 Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof |
| 07/11/2002 | US20020091127 Semicarbazides and their uses |
| 07/11/2002 | US20020091126 Folate compound or derivative (such as tetrahydrohydrofolate or 5-methyltetrahydrofolate), tetrahydrobiopterin or mixtures |
| 07/11/2002 | US20020091124 Also used as an antimitotic and for direct and/or indirect inhibition of tubulin polymerization in mammalian |
| 07/11/2002 | US20020091122 Voltage-dependent |
| 07/11/2002 | US20020091121 Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions |
| 07/11/2002 | US20020091119 Aralkyl and aralkylidene heterocyclic lactams and imides |
| 07/11/2002 | US20020091118 Psychotherapeutic agents. |
| 07/11/2002 | US20020091117 Psychotherapeutic agents. |
| 07/11/2002 | US20020091115 Aza-bridged-bicyclic amino acid derivatives as alpha4 integrin antagonists |
| 07/11/2002 | US20020091111 Bile salt conjugates |
| 07/11/2002 | US20020091105 Useful for treating immune mediated diseases and conditions, such as bone marrow, organ and tissue transplant rejection. |
| 07/11/2002 | US20020091104 Protein tyrosine phosphatases inhibitors, especially as antidiabetic agents |
| 07/11/2002 | US20020091088 Administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone |
| 07/11/2002 | US20020091084 Human calcineurin B-like protein (CAB) and polynucleotides which identify and encode CAB. |
| 07/11/2002 | US20020091079 An empty sc-MHC class II molecule comprising a peptide binding groove and a class II beta 2 chain comprising at least one amino acid substitution or deletion; immunosuppressants |
| 07/11/2002 | US20020091078 Treating diabetes, especially Type II diabetes |
| 07/11/2002 | US20020090715 Method for the preparation of a viral vector by inter-molecular homologous recombination |
| 07/11/2002 | US20020090695 Kunitz-type protease inhibitor polynucleotides, polypeptides, and antibodies |
| 07/11/2002 | US20020090670 Cysteine/glycine rich peptides |
| 07/11/2002 | US20020090658 Diagnosing connective tissue defects; obtain sample, screen sample for the presence of degradation protein, amplified concentrations of protein indicate connective tissue defects |
| 07/11/2002 | US20020090624 Gene markers useful for detecting skin damage in response to ultraviolet radiation |
| 07/11/2002 | US20020090622 Detection of a polymorphism in a sodium transport protein; obtain sample, recover nucleotide sequences from sample, determine nucleotide sequences of sample, compare to control |
| 07/11/2002 | US20020090406 Tahitian noni juice on COX-1 and COX-2 and tahitian noni juice as a selective COX-2 inhibitor |
| 07/11/2002 | US20020090397 Novel suppository form comprising an acid-labile active compound |
| 07/11/2002 | US20020090384 Anti-irritant compositions containing a cyclic nucleotide |
| 07/11/2002 | US20020090373 ADAMTS polypeptides, nucleic acids encoding them, and uses thereof |
| 07/11/2002 | US20020090368 Therapeutic uses of bactericidal/permeability increasing (BPI) protein products |